3D Global Biotech Inc.

Taipei Exchange 6808.TWO

3D Global Biotech Inc. Receivables for the year ending December 31, 2023: USD 63.06 K

3D Global Biotech Inc. Receivables is USD 63.06 K for the year ending December 31, 2023, a 26.27% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • 3D Global Biotech Inc. Receivables for the year ending December 31, 2022 was USD 49.94 K, a -15.63% change year over year.
  • 3D Global Biotech Inc. Receivables for the year ending December 31, 2021 was USD 59.20 K, a -27.07% change year over year.
  • 3D Global Biotech Inc. Receivables for the year ending December 31, 2020 was USD 81.17 K, a -23.34% change year over year.
  • 3D Global Biotech Inc. Receivables for the year ending December 31, 2019 was USD 105.87 K.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
Taipei Exchange: 6808.TWO

3D Global Biotech Inc.

CEO Ruiwen Huang
IPO Date Dec. 25, 2020
Location
Headquarters No.99, Xintai 5th Road
Employees 33
Sector Health Care
Industries
Description

3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.

StockViz Staff

January 15, 2025

Any question? Send us an email